🇺🇸 FDA
Patent

US 11912750

GDNF fusion polypeptides and methods of use thereof

granted A61KA61K38/00A61P

Quick answer

US patent 11912750 (GDNF fusion polypeptides and methods of use thereof) held by Keros Therapeutics, Inc. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Keros Therapeutics, Inc.
Grant date
Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/00, A61P, A61P25/00, A61P3/00